Fox Run Management’s Terns Pharmaceuticals TERN Stock Holding History

Fox Run Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,891	Closed	-$359K	–	1231
2025 Q4	$359K	Sell	8,891 -2,719	-23%	-$62.8K	0.06%	636
2025 Q3	$87.2K	Buy	+11,610	New	+$74.1K	0.01%	865
2024 Q3	–	Sell	-16,503	Closed	-$112K	–	1095
2024 Q2	$112K	Buy	+16,503	New	+$100K	0.02%	715

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Fox Run Management's TERN Position: Q1 2026 in Review

Fox Run Management sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 8,891 shares — an estimated $359K sold.

Fox Run Management first reported a position in TERN in Q2 2024 and held it in 3 quarters. The position peaked at $359K in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

Fox Run Management reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Fox Run Management sold 8,891 Terns Pharmaceuticals shares in Q1 2026, an estimated $359K.
Fox Run Management first reported a position in Terns Pharmaceuticals in Q2 2024 and held it in 3 quarters.
Fox Run Management's Terns Pharmaceuticals position peaked at $359K in Q4 2025.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.